Droneshield Limited

DRO

DroneShield Ltd. engages in the development and commercialisation of hardware and software technology for drone detection and security. The company is headquartered in Sydney, New South Wales. The company went IPO on 2016-06-22. The company provides artificial intelligence-based platforms for protection against advanced threats, such as drones and autonomous systems. The company offers customers bespoke counter-drone (or counter-UAS) and electronic warfare solutions and off-the-shelf products designed to suit a variety of terrestrial, maritime, or airborne platforms. The Company’s products include DroneGun Tactical, DroneGun MKIII, DroneSentry, DroneSentry-C2, DroneSentry-X, RfPatrol and DroneSim among others. The DroneGun Tactical is an unmanned aerial systems (UAS) countermeasure designed for two-hand operation and long-range defeat. RfPatrol is a passive/non-emitting wearable UAS detection device. The Company’s capabilities include C-UAS, C-UxS Training, and Electronic Warfare.

Accent Group Limited

AX1

Accent Group Ltd. operates as an investment holding company, which engages in the retail of performance and lifestyle footwear. The company is headquartered in Richmond, Victoria. The company went IPO on 2004-07-07. The firm operates approximately 903 stores across 18 different retail banners, and distribution rights for 12 international brands across Australia and New Zealand. The firm operates through two segments: Retail and Wholesale. The Retail segment is engaged in selling of footwear and apparel directly to consumers. The Wholesale segment is engaged in selling of footwear and apparel in bulk internally and to other businesses. The Company’s banners and brands include Platypus Shoes, The Athlete’s Foot (TAF), Hype DC, Skechers, Merrell, Vans, Dr. Martens, Saucony, Timberland, HOKA, Superga, Subtype, Stylerunner, Glue Store, Nude Lucy and UGG.

Botanix Pharmaceuticals Ltd

BOT

Botanix Pharmaceuticals Ltd. is a dermatology company, which engages in the provision of business of researching and developing dermatology and antimicrobial products. The company is headquartered in Perth, Western Australia. The Company’s lead product is Sofdra (sofpironium) topical gel, 12.45%, a prescription anticholinergic medicine used on the skin (topical), to treat excessive underarm sweating (primary axillary hyperhidrosis) in adults and children nine years of age and older. Sofdra regulates sweating at the site of application, by binding to the primary sweat receptor and thereby blocking the sweat signal. Its product pipeline targets the various skin diseases, such as BTX 1503 for Acne, BTX 1702 for Rosacea, BTX 1204A for Atopic Dermatitis, and BTX 1801 for Hemodialysis Patients. Its BTX 1503 is a transdermal gel formulation for the treatment of serious acne in adults and teenagers. BTX 1702 is used for the treatment of papulopustular rosacea. BTX 1801 is an antimicrobial gel focused on targeting Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus (MRSA).

CSL Limited

CSL

CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. The company is headquartered in Melbourne, Victoria and currently employs 30,398 full-time employees. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with more than 325 plasma collection centers in the United States, Europe and China. The firm operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China. Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam and others.

Lovisa Holdings Limited

LOV

Lovisa Holdings Ltd. engages in the retail sale of fashion jewelry and accessories. The company is headquartered in Hawthorn, Victoria. The company went IPO on 2014-12-18. The firm and its subsidiaries are primarily involved in the retail sale of fashion jewelry and accessories. The firm is also focused on designing, developing, sourcing, and merchandising all its branded products. The firm develops, designs, sources and merchandises 100% of its Lovisa branded products. The company offers a range of products, including earrings, necklaces, rings, body jewelry, and others. The company offers a range of accessories, including hair clips, watches, jewelry boxes, belts, headbands, and others. The firm has over 700 stores across over 30 countries globally, including Australia, New Zealand, Singapore, Malaysia, Hong Kong, Namibia, South Africa, France, Austria, Belgium, Germany, Luxembourg, Netherlands, Poland, Italy, Hungary, Romania, and Switzerland, Canada, Mexico, the United States, the United Kingdom, and franchised stores in the Middle East and South America.